The Schwab U.S. Dividend Equity ETF (SCHD) has attracted significant inflows as investors rotate into defensive plays following a tech-led selloff. However, a closer look reveals that the fund's top 10 holdings now constitute approximately 43.5% of its $95.17 billion in assets, raising concerns about concentration risk. While the fund offers a 30-day SEC yield of 3.24% and a low expense ratio of 0.06%, its performance is increasingly tied to the fortunes of a handful of large-cap stocks.
Market Context
Last Friday, the S&P 500 dropped 2.64%, and the Nasdaq shed 4.18%, driven by a sharp selloff in semiconductor stocks—their worst day since March 2020. Stronger-than-expected jobs data reignited fears that the Federal Reserve might tighten monetary policy, prompting a flight to income-generating assets. On Monday, markets bounced back, with the Dow up 0.29%, the S&P 500 rising 0.68%, and the Nasdaq advancing 1.09%. The Philadelphia semiconductor index jumped 4.6% as chip names rallied.
Art Hogan, chief market strategist at B Riley Wealth, commented to Reuters, "Sometimes these moves get too far too fast and you need a bit of a pullback," suggesting that any correction could push money into other sectors. This environment has made SCHD a popular choice for investors seeking shelter.
Concentration Risk
As of June 4, SCHD's top holdings include Qualcomm (6.51%), Texas Instruments (5.89%), UnitedHealth (5.31%), Chevron, Merck, Coca-Cola, ConocoPhillips, Amgen, Procter & Gamble, and Verizon. Together, these ten stocks represent 43.5% of the fund's assets—a high level of concentration for a portfolio of 103 stocks. In 2022, when the S&P 500 fell 18%, SCHD dropped only 3%, demonstrating its defensive qualities. However, the current weightings mean that any adverse movement in these key holdings could disproportionately affect the fund's performance.
24/7 Wall St. noted that SCHD now has over 40% of assets in its largest positions, with energy and healthcare names making the fund sensitive to oil price swings and drug policy changes. Additionally, the fund's five-year total return lags behind the SPDR S&P 500 ETF Trust (SPY), despite recent outperformance.
Comparison with Peers
The Vanguard High Dividend Yield ETF (VYM) is a close competitor, with 620 holdings, a 0.04% expense ratio, and top positions in Broadcom, JPMorgan Chase, Exxon Mobil, and Johnson & Johnson. While VYM offers broader diversification, it pays a lower yield than SCHD. According to Samuel Smith's High Yield Investor group on Seeking Alpha, investors seeking "higher yield and higher dividend growth" might prefer SCHD, but those prioritizing diversification should consider VYM.
On Monday, SCHD traded at $32.44, up about 0.4%, while VYM rose 0.4% to $158.92, and SPY advanced 0.9%. The broad market rally included gains beyond dividend stocks.
Risks and Outlook
The primary risk for SCHD is that growth stocks could regain leadership. If semiconductor stocks continue to bounce and AI spending drives earnings, dividend funds may underperform, as seen during parts of the 2023-2025 rally. Additionally, higher oil prices or negative healthcare headlines could weigh on SCHD, given its heavy exposure to energy and pharmaceutical sectors.
Citigroup raised its year-end S&P 500 target to 8,100 from 7,700 on Monday, citing earnings strength and an AI "supercycle." However, the bank expressed doubts about the sustainability of AI-driven growth beyond 2027. This underscores the potential for a shift in market leadership away from dividend plays.
In summary, SCHD offers a cheap, income-focused strategy with steady yield, but its growing concentration in a few large stocks introduces risk that investors should not overlook. The fund's future performance may hinge on the trajectory of its top holdings, making it less of a pure safety play than it appears.
